http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1094809-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62f0bff2e3c0016a210cc1021cdec1ac |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-417 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-417 |
| filingDate | 1999-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e773e2313fb74129a6431f1c93eca226 |
| publicationDate | 2001-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1094809-A2 |
| titleOfInvention | Use of histamine h2 mimicking substances for the treatment of multiple sclerosis |
| abstract | Use of a histamine H2 mimicking substance for the manufacture of a medicament for the treatment of multiple sclerosis. The histamine H2 mimicking agent is present in an amount which is effective to stimulate production of a cyclic AMP in the body. A phosphodiesterase inhibitor is used in conjunction with the histamine H2 mimicking agent to conserve the cyclic AMP which is thus produced. It is believed that the increased cyclic AMP levels serve to maintain the patient's myeline against self degeneration. The histamine H2 mimicking agent may be histamine phosphate and the phosphodiesterase inhibitor may be caffeine. The histamine H2 mimicking agent and the phosphodiesterase inhibitor may be mixed in a gel and administered using a transdermal patch. |
| priorityDate | 1998-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.